Nanobiotix (NBTX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.56B and a free-cash-flow yield of -2.6%. Nama's AI scorecard rates it Sell, 2.2 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Sell · 2.2/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Middle · +25.2% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-46.4%
How far the last close sits under the highest price of the past five years.
Market cap
$1.56B
Trailing P/E
—
Price / book
—
Price / sales
122.5
FCF yield
-2.6%
Dividend yield
—
Gross margin
100.0%
Operating margin
-322.9%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.6
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
NBTX earnings
Beat the EPS estimate in 1 of 1 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q1 2022
Apr 7, 2022
-$0.20
-$1.06
+81.1%
—
NBTX analyst price target
Median target $62.73 from 3 analysts, ranging $30.00 – $69.66.
Nama's AI scorecard currently rates Nanobiotix Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the NBTX price target?
The median analyst price target from 3 analysts is $62.73, with a range of $30.00 – $69.66.
Is NBTX Shariah compliant?
Nama's AAOIFI-style screen reads Nanobiotix as Can't Tell. A figure the screen needs is missing, so it can't tell.